EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial

Tim Heise iD, Eric Zijlstra iD, Andrea Mari, William C Roell, Kieren J Mather iD, Axel Haupt iD, Panagiotis Flevaris, Ran Liao, Laiyi Chua, Charles Harris, Edward J Pratt iD

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70863 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Tim Heise und 10 weiteren Autor:innen. Beteiligte Einrichtung: Profil, Neuss, Germany. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Immunoglobulin Fc Fragments, Recombinant Fusion Proteins. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly and Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This Phase 1b, randomised, double‐blind clinical trial investigated the contribution of glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin. Materials and Methods Participants were randomised to receive the long‐acting GIP receptor agonist macupatide, dulaglutide or both combined. Insulin sensitivity ( M value), insulin secretion rate (ISR) and the corresponding clamp disposition index (cDI) were assessed from hyperinsulinemic euglycaemic clamps at baseline and after 12‐week treatment.

Results

Overall baseline means were cDI, 0.3 pmol*m −2 *L*min −2 *kg −1 ; M value, 5.8 mg*kg −1 *min −1 ; ISR, 116.8 pmol*min −1 *m −2 . The 12‐week increases in the macupatide, dulaglutide and combination arms were, respectively: cDI, 0.2 (63.2% change), 0.5 (181.0%) and 1.0 (321.5%); M value, 1.3 (33.1%), 0.2 (10.4%) and 2.0 (38.3%); ISR, 37.6 (32.2%), 191.1 (163.6%) and 225.3 (192.9%). Macupatide alone significantly increased the M value and, to a lesser yet significant extent, ISR. Combination therapy was numerically greater than both monotherapies in augmenting all indices. The most frequent adverse events were injection site reactions and diarrhoea. Study discontinuations due to treatment‐emergent adverse events were uncommon. There were no deaths during the study.

Conclusion

These findings demonstrate that chronic GIP receptor activation in individuals with T2D leads primarily to increased insulin sensitivity, and that combining GIP and GLP‐1 receptor agonism can augment both insulin secretion and insulin sensitivity compared to GLP‐1 therapy alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Glucagon-Like PeptidesImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsHypoglycemic AgentsInsulin ResistanceInsulin-Secreting CellsHumansMaleFemaleMiddle AgedDouble-Blind MethodDrug Therapy, CombinationAgedInsulin SecretionReceptors, Gastrointestinal HormoneInsulinBlood GlucoseMetformin

Stichwörter der Autor:innen

GIPGLP‐1beta cell functionclinical trialdulaglutidetype 2 diabetes

Substanzen

dulaglutideGlucagon-Like PeptidesImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsHypoglycemic AgentsReceptors, Gastrointestinal HormoneInsulinBlood GlucoseMetformingastric inhibitory polypeptide receptor

Autor:innen und Institutionen

  • Profil, Neuss, Germany.
  • Institute of Neuroscience, National Research Council (CNR) of Padova, Padova, Italy.
  • Eli Lilly and Company, Indianapolis, Indiana, USA.

ORCID-Profile: Tim Heise, Eric Zijlstra, Kieren J Mather, Axel Haupt, Edward J Pratt

Förderung

  • Eli Lilly and Company

Zitieren

APA

Heise, T., Zijlstra, E., Mari, A., Roell, W. C., Mather, K. J., Haupt, A., Flevaris, P., Liao, R., Chua, L., Harris, C., & Pratt, E. J. (2026). Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70863

Vancouver

Heise T, Zijlstra E, Mari A, Roell WC, Mather KJ, Haupt A, et al. Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70863

BibTeX
@article{Heise2026,
  author = {Heise, Tim and Zijlstra, Eric and Mari, Andrea and Roell, William C and Mather, Kieren J and Haupt, Axel and Flevaris, Panagiotis and Liao, Ran and Chua, Laiyi and Harris, Charles and Pratt, Edward J},
  title = {Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70863}
}
Kostenlos starten →